In conjunction, a broad range of TNF inhibitor formulations are currently being used, particularly humanized TNF-α-inhibitors, namely adalimumab and infliximab, to treat COVID-19 and ameliorate cytokine storm [130,157]. The gene discussed is TNF; the disease is COVID-19.